'Mankind's experience, sharpness, and execution will make it happen. We are not going for short-term gains.'
Firm says the proposed drones can also be used to identify other such objects, along with aircraft, plying within Indian skies
The CBI lodged the case after a two-year preliminary enquiry, which originated from a pen drive handed over to the then Maharashtra Assembly speaker by Devendra Fadnavis, who was in the opposition in 2020, they said.
India rejects patent on Pfizer's arthritis drug
Xiaomi will start pre-loading Microsoft Office and Skype on its phones starting September 2016, initially in China, with other markets including India to follow.
'There are ominous portents of an isolationist administration not only building a physical wall to the south to prevent unwanted immigrants from entering the land of milk and honey, but also trade walls not just against China, but all nations,' foresees Sreekant Sambrani.
Flash Electronics alleges Royal Enfield infringed its patent on regulator rectifier device.
The patent department made this declaration on August 16 after Novartis had failed to respond to its queries within the prescribed time.
China has consistently spent more than 2% of GDP on R&D while India's expenditure on R&D has stagnated around 0.7% of GDP. Can our government shore up resources so that we hit the R&D expenditure target of 2% of GDP set out by the Science, Technology and Innovation Policy of 2013, asks Chidambaran G Iyer, Senior Fellow, Pahle India Foundation.
For now, Modi's government appears singularly focussed on demonstrating that it is not in any way inhibited by the BJP's loss of a majority, and will continue along its patented path of bulldozing all opposition and doing just as it likes, asserts Prem Panicker.
Infosys' spending on research and development has registered a decline.
Innovation is coming to the US from abroad these days, and foreign applications are coming faster and faster.
The venue of the battle by Swiss multinational Novartis AG against the rejection of its patent application for blockbuster cancer drug Gleevac will now shift to the Patent Appellate Board's office.
Apple had taken Shanghai-based Zhizhen Internet Technology and China's State Intellectual Property Office to court to seek a ruling that Zhizhen's patent rights to a speech recognition technology were invalid.
The domestic pharmaceutical industry and non-government organisations are up in arms against the first ever Indo-US tie-up on intellectual property rights
Both firms have made several applications for patents pertaining to digital payments in the country
Patients' lobbies cheer ruling on anti-cancer drug Glivec, as affordability and access to life-saving drugs get a leg-up.
These patents are primarily in the area of computation and data processing.
India's IPR framework and enforcement were comparable to those in developed countries
Throughout its 155 minutes, every scene is doused in blaring background music and melodrama. Disappointment alone won't do, it must feel like a full blown catastrophe, observes Sukanya Verma.
Microsoft India development centre is betting big on its Hyderabad operations. In 2005-06, it is planning to file applications for 70 patents for various projects that are underway at its centre. MIDC filed for 40 patents in 2004-05.
More than 3,000 gifts for Lord Ram from Sita's birthplace in Janakpur in Nepal have arrived in Ayodhya.
The Uttar Pradesh Export Corporation Limited (UPECL), a state government undertaking engaged in the development and marketing of handicrafts and handloom items produced in Uttar Pradesh, is set to apply for patenting of Lucknow chikan. Once the office of Intellectual Property Rights (IPR) gives its certificate, chikan would exclusively be linked with Lucknow city.
Bharatiya Janata Party candidate Mukesh Dalal was on Monday elected unopposed from Surat Lok Sabha constituency in Gujarat after all other nominees withdrew from the fray, a poll official said.
Several Indian units of American technology companies have filed more than 1,000 patent applications with the US Patent and Trademark office, a media report said on Tuesday.
In a boost to India's biggest drugmaker Ranbaxy Laboratories Ltd, an Austrian panel has ruled in the company's favour in a patent litigation against Pfizer involving cholesterol lowering drug 'Lipitor' in that country.
The speaker had, in an order on January 10, declared the Shiv Sena bloc led by Shinde as the 'real political party' after its split in June 2022.
'However, we have seen weakness in our active pharmaceutical ingredients business.'
In a development that might result in India's leading drug maker Ranbaxy selling a generic version of Pfizer's blockbuster drug Lipitor sooner than expected in the US market, the United States patent office has made an initial rejection of Pfizer's claim on the basic patent on Lipitor.
Apple still has a request pending for a sales ban against newer Samsung phones in that proceeding.
'Even for operational buildings, we are looking to smarten them in various ways.'
India was among the 14 countries, including Pakistan and Russia, which remained on the 'Priority Watch Lis't of the United States for "inadequate and ineffective" enforcement of patent laws.
The strong IPR protection across the board -- patents, trademark and copyright - had been a lynchpin in the success of the US services sector, he added.
The CBI, in its FIR, alleged that Mayaram, the UK-based company De La Rue International Ltd and unidentified officials of the finance ministry and RBI hatched a criminal conspiracy to extend undue favour to the firm.
The government has also set targets for the next 25 years. We are working on the target of becoming a $5-10 trillion economy as well as taking exports to a record high, he said.
In Phase 6, indications are that the BJP, which is defending 40 seats, will lose in double digits and gain in single digits. Not good, if you are the ruling party scrambling to earn a working majority, with just one phase left to go, argues Prem Panicker.
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances